Treatment with Tocilizumab in mouse models of hormone-therapy-resistant breast cancer can also re-sensitize tumors to Tamoxifen treatment, highlighting the importance of the IL-6-IL-6R-ER axis in hormone receptor positive disease [94]. Here, IL6R is linked to breast cancer.